JAKAVI 25MG

Description

Jakavi 25mg belongs to type of targeted therapy which performs as oral receptor tyrosine kinase inhibitor

Jakavi 25mg also an ATP-competitive inhibitor of JAK1 and JAK2 and prohibition resulted regardless of the JAK2V617F mutational status.

Jakavi 25mg is prescription drug provided under supervision of

Indication

Jakavi 25mg is indicated for the treatment in patients with intermediate and high-risk myelofibrosis.

Mechanism of action

Ruxolitinib belongs to a type of drug called a protein kinase inhibitor.

Genes known as JAK1 and JAK2 help regulate the number of blood cells the body makes. If either of these genes become damaged, the body may make more blood cells. Ruxolitinib inhibits the indication that are sent by the damaged gene. This helps decrease the number of extra blood cells which are made.

Ruxolitinib can stop other signs that cause more blood cells to be made. So, it can also work for people who do not have a damaged JAK gene.

ADME Properties

Absorption: fast absorption and not affected by food maximum plasma level is 1.5 hours.

Distribution: volume of distribution is 76.6 L plasma protein binding is

Metabolism: metabolized by CYP3A4

Elimination: excreted through urine 74% and unchanged drug is <1% and through urine 22% , <1 % as unchanged drug

Dosage and administration

Myelofibrosis

Starting recommended doses for myelofibrosis

If Platelet count >200 x10^9/L the prescribed dose is 20 mg PO BID

If Platelet count 100-200 x10^9/L the prescribed dose is 15 mg PO BID

If Platelet count 50 to <100 x10^9/L the prescribed dose is 5 mg PO BID

Titrate dose based on response; not to exceed 25 mg PO BID

Polycythemia Vera

The prescribed dose is 10mg PO BID

Undergo CBC and platelet count prior starting and q2-4wk until doses are stabilized, and then as clinically used.

Side effects

Common side effects caused due to Jakavi 25mg

• low red blood cell
• low in platelet counts

Serious side effects caused due to Jakavi 25mg

• High Cholesterol level
• Dyspnea
• Nasopharyngitis
• Headache
• Constipation
• Nausea & Vomiting
• sleeplessness
• raised in liver enzymes
• Diarrhea
• bleeding
• Swelling
• Neutropenia
• Dizziness

Drug interaction

Concomitant use with fluconazole doses greater than 200mg daily may increase Ruxolitinib exposure leads to increase the risks of exposure related adverse reaction.

Concomitant use of Jakavi 25mg with strong CYP3A4 inhibitors will increases Ruxolitinib exposure.

Concomitant use of Jakavi 25mg with strong CYP3A4 inducers will decreases Ruxolitinib exposure.

Contraindication

Hypersensitivity

Precautions

Therapy  with Jakavi 25mg can resulted in  thrombocytopenia, Anemia and neutropenia. Regulate thrombocytopenia by reducing the dose or temporarily inhibit Jakavi 25mg. Platelet transfusions may be required.

Risk of infection occurs by delay initiate treatment with Jakavi 25mg until active severe infection have resolved.

Tuberculosis infection has been resulted in patients administrating Jakavi 25mg. monitor patients getting Jakavi 25mg for signs and symptoms of active tuberculosis and manage promptly.

Progressive multifocal leukoencephalopathy (PML) has reported with Jakavi 25mg treatment. If PML is suspected, discontinue Jakavi 25mg and evaluate

Non-melanoma skin cancers containing basal cell, squamous cell, and Merkel cell carcinoma have reported in patients getting with Jakavi 25mg. Do the periodic skin examinations.

Pregnancy

The drug has no studies with the Jakavi 25mg use in pregnant women to inform drug-along with risks. Hence avoid becoming pregnancy during Jakavi 25mg treatment

Lactation

Do not breast feed to infants during treatment with Jakavi 25mg. Excretion into human milk is unknown

Storage

Jakavi 25mg stored at 20⁰C to 25⁰C

Protect away from light and moisture

Dispense in its original container

Missed dose

If dose is forgot, then have the dose immediately before next dose timing reaches or skip the missed dose and follow the regular schedule.

Discuss with doctors regarding missed dose.